JP2018519803A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519803A5
JP2018519803A5 JP2017560331A JP2017560331A JP2018519803A5 JP 2018519803 A5 JP2018519803 A5 JP 2018519803A5 JP 2017560331 A JP2017560331 A JP 2017560331A JP 2017560331 A JP2017560331 A JP 2017560331A JP 2018519803 A5 JP2018519803 A5 JP 2018519803A5
Authority
JP
Japan
Prior art keywords
ser
arg
tyr
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519803A (ja
JP6947642B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/061071 external-priority patent/WO2016184882A1/en
Publication of JP2018519803A publication Critical patent/JP2018519803A/ja
Publication of JP2018519803A5 publication Critical patent/JP2018519803A5/ja
Application granted granted Critical
Publication of JP6947642B2 publication Critical patent/JP6947642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560331A 2015-05-18 2016-05-18 抗がん性融合ポリペプチド Active JP6947642B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15167927.1 2015-05-18
EP15167927 2015-05-18
EP16150508 2016-01-08
EP16150508.6 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Publications (3)

Publication Number Publication Date
JP2018519803A JP2018519803A (ja) 2018-07-26
JP2018519803A5 true JP2018519803A5 (https=) 2019-06-20
JP6947642B2 JP6947642B2 (ja) 2021-10-13

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560331A Active JP6947642B2 (ja) 2015-05-18 2016-05-18 抗がん性融合ポリペプチド

Country Status (22)

Country Link
US (2) US10913778B2 (https=)
EP (2) EP3298030B1 (https=)
JP (1) JP6947642B2 (https=)
KR (1) KR102685748B1 (https=)
CN (1) CN108112253B (https=)
AU (1) AU2016262845B2 (https=)
CA (1) CA2980838A1 (https=)
DK (1) DK3298030T5 (https=)
ES (1) ES2938525T3 (https=)
FI (1) FI3298030T3 (https=)
HR (1) HRP20230145T1 (https=)
HU (1) HUE061108T2 (https=)
LT (1) LT3298030T (https=)
MX (1) MX390894B (https=)
PL (1) PL3298030T3 (https=)
RS (1) RS64002B1 (https=)
RU (2) RU2021119777A (https=)
SG (1) SG11201707426SA (https=)
SI (1) SI3298030T1 (https=)
SM (1) SMT202300026T1 (https=)
WO (1) WO2016184882A1 (https=)
ZA (1) ZA201706061B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CN114573680A (zh) * 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
WO2017009456A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2018127473A1 (en) * 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
EP3565841A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CA3050194A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EP3710478A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019185598A1 (en) 2018-03-26 2019-10-03 4Sc Ag Combination comprising hdac inhibitor and cd137 agonist for cancer therapy
FI3830120T3 (fi) * 2018-07-31 2023-06-13 Pieris Pharmaceuticals Gmbh CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini
SG11202106353VA (en) * 2019-02-26 2021-07-29 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
EP3946417A1 (en) * 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
JP7301155B2 (ja) * 2019-04-12 2023-06-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
JP2025532652A (ja) * 2022-09-21 2025-10-01 シージェン インコーポレイテッド Cd137およびcd228に特異的な新規融合タンパク質

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
MX9605717A (es) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DK1087778T3 (da) 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU2001294617A1 (en) 2000-09-21 2002-04-02 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス, インコーポレイテッド タンパク様薬剤およびその使用
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
EP2046820B1 (en) 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
ES2354653T3 (es) 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
ME02345B (me) 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
WO2009052400A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
DK3381933T3 (da) 2008-06-24 2020-08-03 Technische Universität München Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
RU2707126C2 (ru) 2009-12-07 2019-11-22 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
EP3299386A1 (en) 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
MX337040B (es) * 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
US9522940B2 (en) * 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
CA2913029A1 (en) * 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
AU2015244814B2 (en) * 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
CR20170425A (es) 2015-02-18 2017-11-22 Sanofi Sa Nuevas proteínas específicas para pioverdina y pioquelina
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
CN114573680A (zh) * 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
MX2017014730A (es) 2015-05-18 2018-06-28 Pieris Pharmaceuticals Gmbh Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Similar Documents

Publication Publication Date Title
JP2018519803A5 (https=)
JP2018515085A5 (https=)
JP2018526989A5 (https=)
RU2017135539A (ru) Слитый полипептид с противораковой активностью
RU2017135596A (ru) Слитый полипептид с противораковой активностью
RU2018107991A (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
JP2021533203A5 (https=)
JP2017527272A5 (https=)
JP2018515084A5 (https=)
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
JP2022523524A5 (https=)
CN114728040A (zh) 新型白介素-2变体及其双功能融合分子
FI3830120T3 (fi) CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2015524799A5 (https=)
JP2018532372A5 (https=)
JP2011501951A5 (https=)
JP2019502694A (ja) 二特異性抗体基幹
JP2017518748A5 (https=)
JP2019506140A5 (https=)
Plaksin et al. A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes
JP2019505565A5 (https=)
TW202233694A (zh) 雙特異性抗體
KR20210091220A (ko) 부착된 세포에 직접 신호를 보내지 않는 비-천연 nkg2d 수용체
CA3250782A1 (en) HIV-SPECIFIC BINDING MOLECULES AND TCR